Baricitinib versus placebo or adalimumab in rheumatoid arthritis

Slični predmeti

• Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’une étude de phase 3 de 52 semaines RA-BEAM
  od: Taylor, P, i dr.
  Izdano: (2016)
• Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
  od: Keystone, E, i dr.
  Izdano: (2017)
• Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
  od: Taylor, P, i dr.
  Izdano: (2017)
• Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
  od: Emery, P, i dr.
  Izdano: (2017)
• Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
  od: Taylor, P, i dr.
  Izdano: (2016)